Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy and enhancing the quality of life for patients undergoing treatment with EGFR (Epidermal Growth Factor Receptor) Inhibitors or radiation. The most common adverse reaction to these therapies is dermal toxicity, which often leads to compliance issues. Lutris Pharma is dedicated to developing novel topical therapies that significantly reduce these side effects, enabling patients to adhere to effective anti-cancer treatments.

Lutris Pharma's flagship product, LUT014, is a topical B-Raf Inhibitor, a groundbreaking small molecule that allows uninterrupted administration of EGFR Inhibitors to patients by mitigating cutaneous side effects. By leveraging the paradoxical effect of B-Raf Inhibitors, LUT014 effectively decreases dermal toxicities and acneiform lesions associated with EGFR Inhibitors and radiation-induced dermatitis. The efficacy and safety of LUT014 have been demonstrated through successful Phase 1 and Phase 1/2 trials in colorectal and breast cancer patients respectively.

Lutris Pharma is now conducting a Phase 2 clinical trial in leading US oncological centers, with regulatory oversight from the FDA's Oncology Division. With a commitment to innovation and patient-centered care, Lutris Pharma is paving the way for improved anti-cancer therapy outcomes